Aug. 24 at 2:07 PM
$GANX My two top small biotech names continue to be, Gain and Coya
$COYA. I expect both may ultimately make an important impact both on humanity and shareholders accounts. Both are likely acquisition targets over the next six months in my opinion as pharma looks for compelling CNS assets trying to backfill dwindling pipelines as the patent cliff approaches.
You've all also heard the statement...follow the smart money.
Ironically, both Gain and Coya represent the two smallest market cap companies by a mile in billionaire David Einhorn's own portfolio. He owns about 540K shares of Gain and about 1.6 million of Coya.
When someone of his stature takes large positions in small companies like these that are clearly oit of rhe norm compared to his other holdings, there is generally a reason for it. Considering he sits on the board of the Michael J Fox Foundation, he likely has his finger on the pulse of what is encouraging in terms of addressing numerous neurodegenerative diseases.
https://finance.yahoo.com/news/gain-therapeutics-ganx-top-healthcare-185925734.html
